These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21954603)

  • 1. [Thermodynamics of calmodulin and tubulin binding to the vinca-alkaloid vinorelbine].
    Tsvetkov FO; Kulikova AA; Devred F; Zerniĭ EIu; Lafitte D; Makarov AA
    Mol Biol (Mosk); 2011; 45(4):697-702. PubMed ID: 21954603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S; Vulevic B; Correia JJ
    Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Energetics of vinca alkaloid interactions with tubulin.
    Lobert S; Correia JJ
    Methods Enzymol; 2000; 323():77-103. PubMed ID: 10944748
    [No Abstract]   [Full Text] [Related]  

  • 4. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
    Chi S; Xie W; Zhang J; Xu S
    J Biomol Struct Dyn; 2015; 33(10):2234-54. PubMed ID: 25588192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
    Kelly EB; Tuszynski JA; Klobukowski M
    J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles.
    Li W; Shao Y; Hu L; Zhang X; Chen Y; Tong L; Li C; Shen X; Ding J
    Cancer Biol Ther; 2007 May; 6(5):787-94. PubMed ID: 17387272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elaboration of simplified vinca alkaloids and phomopsin hybrids.
    Ngo QA; Roussi F; Thoret S; Guéritte F
    Chem Biol Drug Des; 2010 Mar; 75(3):284-94. PubMed ID: 20659111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
    Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
    Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of C-13' substituted 7'-homo-anhydrovinblastine derivatives.
    Gherbovet O; La Spisa F; Thoret S; Alvarez MCG; Levaique H; Bignon J; Roussi F
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1771-1773. PubMed ID: 25804719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel aspects of natural and modified vinca alkaloids.
    Duflos A; Kruczynski A; Barret JM
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):55-70. PubMed ID: 12678751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HURP binding to the vinca domain of β-tubulin accounts for cancer drug resistance.
    Saju A; Chen PP; Weng TH; Tsai SY; Tanaka A; Tseng YT; Chang CC; Wang CH; Shimamoto Y; Hsia KC
    Nat Commun; 2024 Oct; 15(1):8844. PubMed ID: 39397030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids.
    Coderch C; Morreale A; Gago F
    Anticancer Agents Med Chem; 2012 Mar; 12(3):219-25. PubMed ID: 22044006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
    Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
    Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
    Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
    Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.
    Lobert S; Ingram JW; Hill BT; Correia JJ
    Mol Pharmacol; 1998 May; 53(5):908-15. PubMed ID: 9584218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of vinorelbine in the cancer therapy.
    Galano G; Caputo M; Tecce MF; Capasso A
    Curr Drug Saf; 2011 Jul; 6(3):185-93. PubMed ID: 22122393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential in vitro association of vinca alkaloid-induced tubulin spiral filaments into aggregated spirals.
    Verdier-Pinard P; Garès M; Wright M
    Biochem Pharmacol; 1999 Sep; 58(6):959-71. PubMed ID: 10509748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.